Immunodeficiency in the lupus clinic

Lupus

Volumn 15, Issue 3, 2006, Pages 127-131

  Karim, M Y ^a,b  

^a FRIMLEY PARK HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antibody; B cell; B lymphocyte; Hypogammaglobulinaemia; Immunodeficiency; Lupus

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HUMORAL ANTIBODY; MANNOSE BINDING LECTIN;

B LYMPHOCYTE; CONFERENCE PAPER; DISEASE ASSOCIATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOGAMMAGLOBULINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; NEUTROPHIL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGAMMAGLOBULINEMIA; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, NATURAL; IMMUNOLOGIC DEFICIENCY SYNDROMES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MANNOSE-BINDING LECTIN;

EID: 33646016280     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2282rr     Document Type: Conference Paper

References (27)

1. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344: 1140-1144.
2. Hudson-Peacock MJ, Joseph SA, Cox J, Munro CS, Simpson NB. Systemic lupus erythematosus complicating complement type 2 deficiency: successful treatment with fresh frozen plasma. Br J Dermato 1997; 136: 388-392.
3. Tsutsumi A, Sasaki K, Wakamiya N et al. Mannose-binding lectin gene: polymorphisms in Japanese patients with systemic lupus erythematosus, rheumatoid arthritis and Sjogren's syndrome. Genes Immun 2001; 2: 99-104.
4. Horiuchi T, Tsukamoto H, Morita C et al. Mannose binding lectin (MBL) gene mutation is not a risk factor for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Japanese. Genes Immun 2000; 1: 464-466.
5. Mok MY, Jack DL, Lau CS et al. Antibodies to mannose binding lectin in patients with systemic lupus erythematosus. Lupus 2004; 13: 522-528.
6. Seelen MA, Trouw LA, van der Hoorn JW et al. Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol 2003; 134: 335-343.
7. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol 2003; 40: 423-429.
8. Horiuchi T, Gondo H, Mivagawa H et al. Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun 2005; 6: 162-166.
9. Peterslund NA, Koch C, Jensenius JC, Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001; 358: 637-638.
10. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999; 353: 1049-1053.
11. Garred P, Voss A, Madsen HO, Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2001; 2: 442-450.
12. Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, Christian CL. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol 1992; 19: 1191-1194.
13. Foster HE, Malleson PN, Petty RE, Roberton DM, Cabral DA. Pneumocystis carinii pneumonia in childhood systemic lupus erythematosus. J Rheumatol 1996; 23: 753-756.
14. Rankin EC, Isenberg DA. IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Lupus 1997; 6: 390-394.
15. Lee AH, Levinson AI, Schumacher HR Jr. Hypogammaglobulinemia and rheumatic disease. Semin Arthritis Rheum 1993; 22: 252-264.
16. Swaak AJ, van den Brink HG. Common variable immunodeficiency in a patient with systemic lupus erythematosus. Lupus 1996; 5: 242-246.
17. Cronin ME, Balow JE, Tsokos GC. Immunoglobulin deficiency in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1989; 7: 359-364.
18. Tarrant TK, Frazer DH, Ava-Ay JP, Patel DD. B cell loss leading to remission in severe systemic lupus erythematosus. J Rheumatol 2003; 30: 412-414.
19. Sussman GL, Rivera VJ, Kohler PF. Transition from systemic lupus erythematosus to common variable hypogammaglobulinemia. Ann Intern Med 1983; 99: 32-35.
20. Goldstein R, Izaguirre C, Smith CD, Mierins E, Karsh J. Systemic lupus erythematosus and common variable panhypogammaglobulinemia: a patient with absence of circulating B cells. Arthritis Rheum 1985; 28: 100-103.
21. Stein A, Winkelstein A, Agarwak A. Concurrent systemic lupus erythematosus and common variable hypogammaglobulinemia. Arthritis Rheum 1985; 28: 462-465.
22. Draft PIN guidelines. 7.01 Diagnosis of Common Variable Immunodeficiency. Retreived 19 January 2006 from http://www.ukpin.org.uk/guidelines7-01.html
23. Warnatz K, Wehr C, Drager R et al. Expansion of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. Immunobiology 2002; 206: 502-513.
24. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066.
25. Jonas MM, Baron MJ, Bresee JS, Schneider LC. Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 1996; 98: 211-215.
26. Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-2154.
27. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590.